Literature DB >> 9100984

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.

M Feldmann1, M J Elliott, J N Woody, R N Maini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9100984     DOI： 10.1016/s0065-2776(08)60891-3

Source DB:  PubMed          Journal:  Adv Immunol        ISSN： 0065-2776            Impact factor:   3.543


× No keyword cloud information.
  43 in total

Review 1.  Access to disease modifying treatments for rheumatoid arthritis patients.

Authors:  D E Furst; F C Breedveld; G R Burmester; L Crofford; P Emery; M Feldman; J R Kalden; A Kavanaugh; E Keystone; P E Lipsky; R N Maini; L Moreland; J S Smolen; L Van De Putte; T Vischer; M Weinblatt; M Weissman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Future prospects for anti-cytokine treatment.

Authors:  M Feldmann; J Miotla; E Paleolog; R Williams; A M Malfait; P Taylor; F M Brennan; R N Maini
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 3.  Infliximab treatment for Crohn's disease.

Authors:  C A Conroy; R Cattell
Journal:  Postgrad Med J       Date:  2001-07       Impact factor: 2.401

4.  Cytokines and cellular interactions in inflammatory synovitis.

Authors:  W P Arend
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 5.  Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.

Authors:  Richard Long; Michael Gardam
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

6.  C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis.

Authors:  S Youssef; G Maor; G Wildbaum; N Grabie; A Gour-Lavie; N Karin
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

7.  Optimizing infliximab therapy for inflammatory bowel disease- the tools are getting sharper.

Authors:  Marie-France Dubeau; Subrata Ghosh
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-02

Review 8.  The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis.

Authors:  G Camussi; E Lupia
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 9.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.

Authors:  K Yoshizaki; N Nishimoto; M Mihara; T Kishimoto
Journal:  Springer Semin Immunopathol       Date:  1998

10.  Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.

Authors:  C Eriksson; S Engstrand; K-G Sundqvist; S Rantapää-Dahlqvist
Journal:  Ann Rheum Dis       Date:  2004-08-05       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.